Steps to Reduce Missed Deadlines and Unnecessary Costs in Research Studies and Trials
September 30, 2020
High cost along with patient recruitment and retention pose major obstacles to conducting clinical trials in the U.S. According to the Tufts Center for the Study of Drug Development (CSDD), it now costs up to $2.6 billion to bring a new drug to market, and according to a study by the Center for Information and Study on Clinical Research Participation (CISCRP), 80% of clinical studies recruiting patients in the U.S. are delayed due to recruitment problems. Unfortunately, those delays mean it can take longer for innovative medicines to be studied and approved, leaving patients to wait years for new treatment options. What solutions do researchers have to help alleviate these burdens, while also still completing their research?
In this webinar, we will discuss:
- Best ways on how to determine the optimal recruitment timeline
- Benefits of in-home collection, processing and procedures
- How to overcome the challenges of longitudinal studies
Chief Product Officer
Gerald serves as Chief Product Officer at Sanguine. He graduated from UCLA with a Bachelors in Molecular, Cellular and Developmental Biology and has a solid background in clinical research. As a co-founder, Gerald helped establish the laboratory infrastructure, and as CPO his role is centered on patient recruitment and developing software to enable mobile clinical trials.
Head of Feasibility & Study Design
Amanda graduated from Occidental College with a Bachelors in Psychobiology. As the Head of Feasibility & Study Design at Sanguine, Amanda reviews all researcher requests for sampling studies and other Sanguine services, determining how to adapt Sanguine's innovative approach to suit the needs of the requesting researchers while also optimizing study timelines.
Cost: No cost!
Schedule conflict? Register and you'll receive a copy of the recording!